AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01153048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensification of education
Description: The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
Study NCT01000896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: film coated tablet, PO, daily
Study NCT01000896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous, 3 weeks
Study NCT01000896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: intravenous, 3 weeks
Study NCT01484405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: posterior approach
Description: Surgical approach for Total Hip Arthroplasty
Study NCT01484405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterolateral approach
Description: anterolateral surgical approach
Study NCT01143857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2.0 mg/day or Placebo
Study NCT01143857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2.0 mg/day or Placebo
Study NCT00058292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
Study NCT00058292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
Study NCT00196976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ACWY
Description: One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
Study NCT00060424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00060424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00060424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT00060424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00060424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00060424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT00060424 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02870283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Study NCT02870283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Study NCT02870283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Study NCT02374151 — intervention group
Intervention type: DEVICE
Intervention: Electrohysterography
Description: The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
Study NCT00603330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal Stem Cell infusion
Study NCT04104386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telomere Disclosure Impact
Description: Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
Study NCT01276262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: Oral tablets, repeated doses for 21 days (2 x 50mg BID)
Study NCT02469272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Administration of frozen fecal materials into gastrointestinal tract
Study NCT01276262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon® 30 (Oral contraceptive)
Description: Oral tablets, repeated doses
Study NCT01276262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon® 30 (Oral contraceptive)
Description: Oral tablets, repeated doses
Study NCT01276262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets BID, repeated doses for 21 days
Study NCT01111695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApisSept
Description: honey and ionic silver based dressing
Study NCT00239733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-D
Description: 30-minute infusion administered in an outpatient setting
Study NCT03055117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise rehabilitation
Description: Group- based physiotherapy-led exercise rehabilitation
Study NCT03055117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual exercise rehabilitation
Description: Individual physiotherapy-led exercise rehabilitation
Study NCT03055117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Supervised home exercise
Study NCT03055117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Supervised home exercise
Study NCT04676620 — intervention group
Intervention type: PROCEDURE
Intervention: CK surgery
Description: CK and LASIK are both effective methods for the correction of hypeopia. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity, and corneal biomechanics compared with traditional refractive surgeries.
Study NCT01315171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium chain triglycerides
Description: 4 tablespoons/day for 2 weeks
Study NCT04006951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)
Study NCT00804466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoE6
Description: HPV oncoprotein assay
Study NCT00804466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVA System
Description: low-cost colposcope
Study NCT00872235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
Study NCT00872235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets
Study NCT00855621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the subthalamic nucleus
Description: Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
Study NCT03375034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC 20mg
Description: Oral administration of one NDMC 20mg capsule and two Placebo capsules
Study NCT03375034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDMC60mg
Description: Oral administration of three NDMC 20mg capsules
Study NCT03375034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam 1.5mg
Description: Oral administration of three clonazepam 0.5mg capsules
Study NCT03375034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of three Placebo capsules
Study NCT01992588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
Study NCT01992588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.
Study NCT03401775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Description: Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
Study NCT02194595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal insulin and exenatide
Study NCT02194595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin only
Study NCT02194595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin and bolus insulin
Study NCT00583336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShuntCheck
Description: Thermal dilution test for CSF flow
Study NCT03549026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
Study NCT03549026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
Study NCT01583361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin+S-1
Description: S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Study NCT01583361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Oxaliplatin/S-1（SOX）
Description: S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
Study NCT04187313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSTEP2 intervention package
Description: The Intervention will comprise: An electronic notification system, a standardized education about the signs and symptoms of TB and TB management and an individualised plan for each PP with respect to their approach to the diagnosis and management of TB suspects.~The electronic system is a refinement of the electronic referral and report-back system using a mobile phone 'app'. The system will enable essential data to be uploaded, consistent with National TB Control Programme forms.~The education package will be focused on TB suspect identification, provisional diagnosis and referral, including how to use the mobile phone 'app'. We will also develop a simple individualised approach for the management of TB suspects, which takes into account the context around each PP's practice, identifying the most efficient and feasible approach to obtaining a diagnosis and notifying TB patients.
Study NCT01139580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene Foam
Description: Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
Study NCT01139580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
Study NCT01164904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amg 181
Description: Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
Study NCT03797677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MN 4000
Description: Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
Study NCT03796962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: Oral dose
Study NCT04618003 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adaptation of autonomic nervous system to activity in virtual reality
Description: heart rate variability assessed at rest and during a physical activity in virtual reality.
Study NCT03796962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XEN1101
Description: Oral dose
Study NCT02270138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement-to-music video program
Description: Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
Study NCT02104843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir, Asunaprevir and BMS-791325 FDC
Study NCT01104649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Study NCT01104649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Study NCT02104843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02104843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02730949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: Treated group
Study NCT02730949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Control group
Study NCT02931461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Study NCT02931461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Study NCT00185159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: tablets
Study NCT02730949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Control group
Study NCT03789838 — intervention group
Intervention type: OTHER
Intervention: Sepsis rapid response team
Description: Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
Study NCT01485146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: escalating doses
Study NCT03661762 — intervention group
Intervention type: DEVICE
Intervention: CAVA
Description: prototype device for monitoring dizziness
Study NCT03802461 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Feces from healthy donor
Study NCT00584415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GP ablation + PV isolation
Description: All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
Study NCT02739399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Intravenous administration
Study NCT03980730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon 5 mg capsule administered orally, once daily
Study NCT03980730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule administered orally, once daily
Study NCT00428948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as tablets.
Study NCT00428948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as tablets.
Study NCT03406273 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cerebral Spinal (CS) radiation
Description: Surgery plus Cerebral Spinal (CS) radiation
Study NCT00185159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Tablets
Study NCT04084704 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cingal
Description: Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 21-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
Study NCT01680263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval
Study NCT01680263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs/Physical therapy
Description: Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine solution for injection
Description: morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
Study NCT03406273 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (SRS)
Description: Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed \[SRS\])
Study NCT02700347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Study NCT04393493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide intravenous solution
Description: Administrated as an 80 mg intravenous bolus every 24 hours in both arms and then as a continuous infusion dosed according to the experimental arm.
Study NCT04393493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: One 50 mg pill administrated every 24 hours in group B
Study NCT04393493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: One 50 mg pill administrated every 24 hours in group B
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo mouthwash
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mouthwash
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine mouthwash
Description: morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
Study NCT02700347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol